Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma

NCT02207062 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Transformed B-Cell Non-Hodgkin Lymphoma
Refractory Transformed B-Cell Non-Hodgkin Lymphoma

Interventions

DRUG: Ibrutinib
OTHER: Laboratory Biomarker Analysis

Sponsor

University of Washington

Collaborators

[object Object]